1. Home
  2. VERU vs CLIR Comparison

VERU vs CLIR Comparison

Compare VERU & CLIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.27

Market Cap

40.9M

Sector

Health Care

ML Signal

HOLD

Logo ClearSign Technologies Corporation (DE)

CLIR

ClearSign Technologies Corporation (DE)

BUY

Current Price

$4.36

Market Cap

33.3M

Sector

Industrials

ML Signal

BUY

Company Overview

Basic Information
Metric
VERU
CLIR
Founded
1971
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
40.9M
33.3M
IPO Year
1996
2011

Fundamental Metrics

Financial Performance
Metric
VERU
CLIR
Price
$2.27
$4.36
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$22.50
$20.00
AVG Volume (30 Days)
59.8K
16.2K
Earning Date
05-12-2026
04-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$16,296,958.00
$530,000.00
Revenue This Year
N/A
$34.29
Revenue Next Year
N/A
$67.31
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.36
$0.39
52 Week High
$4.59
$7.56

Technical Indicators

Market Signals
Indicator
VERU
CLIR
Relative Strength Index (RSI) 54.76 46.32
Support Level $2.12 $4.18
Resistance Level $2.67 $4.75
Average True Range (ATR) 0.12 0.41
MACD 0.02 -0.05
Stochastic Oscillator 77.14 23.19

Price Performance

Historical Comparison
VERU
CLIR

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

About CLIR ClearSign Technologies Corporation (DE)

ClearSign Technologies Corp is engaged in designing and develop technologies for the purpose of decarbonization and improving key performance characteristics of industrial and commercial combustion systems, including emission and operational performance, energy efficiency and overall cost-effectiveness. Its ClearSign Core technology has been proved to be in full scale industrial test furnaces and boilers and first customer installations are currently operating in normal commercial applications The company offers products that include process burners, boiler burners, flares, and ClearSign Eye. The company operates in one segment: Combustion segment. The products of the company include: Process Burners, Midstream and Power, Flares, Boiler Burners, and Sensing Technology.

Share on Social Networks: